MBOT - ステムセルズ （Microbot Medical Inc. ） ステムセルズ

Microbot Medical Inc. (MBOT) lost ~14% on Friday after aannounicing agreements to raise $1.5M in gross proceeds as part of a registered direct offering. Read more here.

https://www.investing.com/news/assorted/microbot-medical-announces-15-million-registered-direct-offering-432SI-3097328

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT ) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company''s common stock at a purchase price of $2.1375 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series C preferred investment options. The series C preferred investment options to purchase up to 350,878 shares of common stock have an exercise price of $2.075 per share and are immediately exercisable for a period of five and one-half years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about June 6, 2023, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offerings. The gross proceeds to the Company from the offerings are expected to be $1.5 million, before deducting the placement agent''s fees and other offering expenses payable by the Company.

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company’s common stock at a purchase price of $2.1375 per share of common stock in a registered direct offering priced at-the-market under Nasdaq […] The post Microbot Medical Announces $1.5 Million Registered Direct appeared first on Businessfortnight .

HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company’s common stock at a purchase price of $2.1375 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered series C preferred investment options. The series C preferred investment options to purchase up to 350,878 shares of common stock have an exercise price of $2.075 per share and are immediately exercisable for a period of five and one-half years following issuance. The closing of the registered direct offering and the concurrent private placement is expected to occur on or about June 6, 2023, subject to the satisfaction of customary closing conditions.

Widely Published Interventional Radiologist Has Earned Well-Regarded Reputation Working with Prestigious Medical Centers in the U.S. and Europe The addition of Professor O''Sullivan, the Clinical Director of Radiology for the Galway Clinic in Ireland , E xpands the Company''s EU P resence. HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT ) continues to receive global interest from interventional radiologists due to the gap in new innovative technology currently available on the market today. Microbot Medical, the company developing the LIBERTY ® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O''Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company''s Scientific Advisory Board (SAB). The Company believes the combination of his academic and medical experience will be invaluable while it seeks to establish Centers of Excellence throughout the U.S. and Europe in preparation for human clinical trials.

https://www.investing.com/news/assorted/microbot-medical-launches-presence-in-uk-432SI-3032465

Internationally Recognized Academic Leader Awarded the National Institute for Health Research (NIHR) Research Rising Star Award, and Cardiovascular and Interventional Radiology (CVIR) Editors Medal HINGHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), which is rapidly scaling up its internal capabilities with globally renowned members joining its Scientific

Allows Endovascular Procedure to be Performed from the Cath-Lab Control Room, Potentially Minimizing Radiation Exposure and Reducing Physical Strain for the Healthcare Providers Design Patent Complements Existing U.S. and European Design Patents as Feedback During Recent Meetings Continues to Support a Positive User Experience HINGHAM, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT ), announced that Japan is the most recent global jurisdiction to recognize the unique interface design of the LIBERTY ® Robotic System''s remote controller. The design patent, which was issued by the Japan Patent Office (JPO), complements similar design patent allowances in the U.S. and Europe, further strengthening the Company''s global intellectual property (IP) portfolio. "We believe the ability to perform an endovascular procedure remotely, while reducing radiation exposure and the physical strain due to wearing a lead vest for an extensive period of time, is a major benefit to the physician and patients," commented Dr.

The Webinar, Which is Suitable to All Stakeholders Interested in the Future of Endovascular Robotics, Will be Held on Wednesday, December 21, 2022, at 1:00pm ET Dr. Ripal Gandhi, a Renowned Miami-Based Interventional Oncologist, Will Share His Personal Experiences Having Completed Over 100 Endovascular Robotic Surgical Procedures HINGHAM, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT ), the developer of the LIBERTY® Robotic System, the first fully disposable endovascular robotic system, announced that following the success of the first episode of its newly launched "Access-Ability Live by MBOT," the next episode which is geared toward all stakeholders interested in the endovascular robotic space, will be held on Wednesday, December 21, 2022 at 1:00pm ET, and hosted by the Company''s Chief Medical Officer, Dr. Eyal Morag. Dr. Morag''s guest speaker will be Dr. Ripal Gandhi, an interventional oncologist and a member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute physician team where he specializes in minimally invasive treatments for peripheral vascular disease, cancer, and other diseases, and has a history of being an innovator in the Interventional Robotics field, specifically in the Endovascular space.

HINGHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (NASDAQ: MBOT ), announced it will be presenting at the Annual Needham Virtual Healthcare Conference. Harel Gadot, Chairman, President and CEO will provide an overview of the Company and recent progress on Tuesday, April 12 th at 8:45am ET. The live and archived replays of the presentation may be accessed via the ‘Investors'' section, under ‘Presentation + Resources'' of the Company''s website at www.microbotmedical.com . About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT ) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, focused primarily on both natural and artificial lumens within the human body. Microbot''s current proprietary technological platforms provide the foundation for the development of … Full story available on Benzinga.com

Microbot Medical (MBOT) has promoted Rachel Vaknin as its Chief Financial Officer ((CFO)), effective Apr. 1, 2022.Ms

NEW YORK , Jan. 24, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for EXTN, MBOT, JWN, TEF, and ASRT. Full story available on Benzinga.com

Microbot Medical (MBOT) +10%. CymaBay Therapeutics (CBAY) +9%. Aptorum (APM) -13%. G Medical Innovations (GMVD) -11%.